Loading company…
MerLion Pharma develops antibiotics for bacterial infections, led by Finafloxacin, which is approved for acute otitis externa.
Founded in 2002 and headquartered in Singapore, MerLion Pharma sells Xtoro, its Finafloxacin product, to hospitals and clinics and is advancing it for complicated urinary tract infections. In November 2016 it raised USD 2.73 mn in a GROWTH round, valuing the company at USD 45.05 mn. It has completed five deals, and in the latest year reported revenue of USD 222,938.70 with EBITDA of USD 2,446,772.40.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in